Skip to Main Content

An official website of the United States government


The PLCO trial confirmed diagnoses of ovarian cancer through medical record abstraction (MRA) of women whom the trial suspected to have ovarian cancer. Fallopian tube and primary paritoneal cancers as well as low malignant potential tumors were included along with invasive ovarian cancers. MRA was triggered by:

  • A self-report of ovarian cancer on an Annual Study Update (ASU)
  • Abnormal suspicious CA-125 or TVU screening
  • Death certificate indicates ovarian cancer
  • No trial indication of ovarian cancer, but Death Review Committee suspects ovarian cancer based on other indicators
  • Relative contacts screening center and informs it of participant's cancer (this is infrequent)

Note that if the MRA process does not find records indicating ovarian cancer diagnosis, even if a source such as a death certificate indicates ovarian cancer, the ovarian cancer is not considered confirmed.

Cancer diagnosis data can be obtained within the Ovarian dataset.

Summary Available Data
  • ~610 ovarian cancers (90 screen-detected)
  • Intervention arm statistics:
    • ~330 cancers
    • Median age at dx: 70
    • Median years into study at dx: 7.2
  • Control arm statistics:
    • ~280 cancers
    • Median age at dx: 71
    • Median years into study at dx: 7.9
  • Cancer confirmation status (confirmation, report only, no cancer, etc.)
  • Days of randomization to diagnosis
  • Screen-detected versus not screen-detected
  • Staging: Clinical, Path, Combined
  • Histology
  • CA-125 level closest to diagnosis